Navigation Links
Vanderbilt study shows therapeutic bacteria prevent obesity in mice
Date:7/22/2014

A probiotic that prevents obesity could be on the horizon. Bacteria that produce a therapeutic compound in the gut inhibit weight gain, insulin resistance and other adverse effects of a high-fat diet in mice, Vanderbilt University investigators have discovered.

"Of course it's hard to speculate from mouse to human," said senior investigator Sean Davies, Ph.D., assistant professor of Pharmacology. "But essentially we've prevented most of the negative consequences of obesity in mice, even though they're eating a high-fat diet."

Regulatory issues must be addressed before moving to human studies, Davies said, but the findings published in the August issue of the Journal of Clinical Investigation suggest that it may be possible to manipulate the bacterial residents of the gut the gut microbiota to treat obesity and other chronic diseases.

Davies has a long-standing interest in using probiotic bacteria "friendly" bacteria like those in yogurt to deliver drugs to the gut in a sustained manner, in order to eliminate the daily drug regimens associated with chronic diseases.

In 2007, he received a National Institutes of Health Director's New Innovator Award to develop and test the idea.

"The NIH basically said, 'we like this idea, now make it work,'" Davies said. "The New Innovator Award was critical to our success."

Other studies have demonstrated that the natural gut microbiota plays a role in obesity, diabetes and cardiovascular disease.

"The types of bacteria you have in your gut influence your risk for chronic diseases," Davies said. "We wondered if we could manipulate the gut microbiota in a way that would promote health."

To start, the team needed a safe bacterial strain that colonizes the human gut. They selected E. coli Nissle 1917, which has been used as a probiotic treatment for diarrhea since its discovery nearly 100 years ago.

They genetically modified the E. coli Nissle strain to produce a lipid compound called NAPE, which is normally synthesized in the small intestine in response to feeding. NAPE is rapidly converted to NAE, a compound that reduces both food intake and weight gain. Some evidence suggests that NAPE production may be reduced in individuals eating a high-fat diet.

"NAPE seemed like a great compound to try since it's something that the host normally produces," Davies said.

The investigators added the NAPE-producing bacteria to the drinking water of mice eating a high-fat diet for eight weeks. Mice that received the modified bacteria had dramatically lower food intake, body fat, insulin resistance and fatty liver compared to mice receiving control bacteria.

They found that these protective effects persisted for at least four weeks after the NAPE-producing bacteria were removed from the drinking water. And even 12 weeks after the modified bacteria were removed, the treated mice still had much lower body weight and body fat compared to the control mice. Active bacteria no longer persisted after about six weeks.

"We still haven't achieved our ultimate goal, which would be to do one treatment and then never have to administer the bacteria again," Davies said. "Six weeks is pretty long to have active bacteria, and the animals are still less obese 12 weeks out.

"This paper provides a proof of concept," he said. "Clearly, we can get enough bacteria to persist in the gut and have a sustained effect. We would like for that effect to last longer."

Davies noted that the researchers also observed effects of the compounds in the liver, suggesting that it may be possible to use modified bacteria to deliver therapeutics beyond the gut.

The investigators are currently working on strategies to address regulatory issues related to containing the bacteria, for example by knocking out genes required for the bacteria to live outside the treated host.
'/>"/>

Contact: Leigh MacMillan
leigh.macmillan@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related biology news :

1. Vanderbilt-led team to develop microbrain to improve drug testing
2. Yale Universitys Joan Steitz awarded 2012 Vanderbilt Prize
3. Vanderbilt diabetes researchers track cells ability to regenerate
4. Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface
5. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
6. Law that regulates shark fishery is too liberal: UBC study
7. New study will help protect vulnerable birds from impacts of climate change
8. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
9. BYU study: Using a gun in bear encounters doesnt make you safer
10. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
11. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology: